Zydus Lifesciences is on analysts' radar. The stock rose nearly 2% on Wednesday after reporting mixed fourth-quarter results.

The pharma companys Board has recommended a final dividend of Rs 11 per equity share of face value Rs 1 each, representing a ...

Zydus Lifesciences Q4 stuns with margin guidance, but brokerages trim targets — stock ends at Rs 890. Should you follow ...

After a record FY25, the drugmaker sees new growth engines in biologics, vaccines, and devices powering expansion in FY26.

Fast Track Designation is given to drugs that are intended to treat serious conditions and or fill an unmet medical need.

Zydus Lifesciences is innovating a single-device for semaglutide. This device can deliver multiple strengths of the drug. It ...

Results: Net profit for the quarter fell 1% from the year-ago period to ₹1,171 crore. The company reported a one-time loss of ...

Zydus Lifesciences consolidated net profit slipped about 1 per cent year-on-year (Y-o-Y) to ₹1,171 crore in the March quarter ...

Those with ALS have an average survival of around two to five years from diagnosis, with most ALS patients dying from ...

Results: Zydus Lifesciences Q4FY25 net profit dips 1% to Rs 1,244 crore due to exceptional charge; revenue grows 17% to Rs ...

The company's net profit was at Rs 1,182 crore, with revenue at Rs 5,633 crore and EBITDA margin rising to 26.7 percent, in ...

The ‘Easiest Exam’ campaign promotes early detection of breast cancer, amassing over 164 million impressions and encouraging ...